Researchclopedia
Research
Researchers
Institutions
Topics
Submit
About
Search...
⌘
K
Command Palette
Search for a command to run...
Back to research
289 COPERNICUS: A Multinational Pragmatic Phase 2 Trial of Subcutaneous (SC) Amivantamab (Ami) in Common EGFR-Mutated (cEGFRm) NSCLC
2026
0 citations
Journal Article
Field-Weighted Citation Impact:
0.00
Emory Healthcare
Luis Raez
·
University of North Carolina at Pembroke
Jonathan W. Riess
·
UC Davis Comprehensive Cancer Center
Danny Nguyen
·
Hope Foundation
Joshua K. Sabari
·
NYU Langone Health
David Bjork
·
Samuel S. Fleisher Art Memorial
Nichelle Stigger
·
LUNGevity Foundation
Yichuan Xia
·
Johnson & Johnson (United States)
Paul Cifuentes
·
Johnson & Johnson (United States)
Farah Shanoon
·
Johnson & Johnson (United States)
J. Penton
·
Johnson & Johnson (United Kingdom)
Agnes Hultén
·
Johnson & Johnson (United States)
Melissa Johnson
·
Sarah Cannon
289 COPERNICUS: A Multinational Pragmatic Phase 2 Trial of Subcutaneous (SC) Amivantamab (Ami) in Common EGFR-Mutated (cEGFRm) NSCLC | Researchclopedia